RT Journal Article
SR Electronic
T1 Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2-infected cells
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.01.21262969
DO 10.1101/2021.09.01.21262969
A1 Venet, Manon
A1 Sa Ribeiro, Margarida
A1 Décembre, Elodie
A1 Bellomo, Alicia
A1 Joshi, Garima
A1 Villard, Marine
A1 Cluet, David
A1 Perret, Magali
A1 Pescamona, Rémi
A1 Paidassi, Helena
A1 Walzer, Thierry
A1 Allatif, Omran
A1 Belot, Alexandre
A1 Assant, Sophie
A1 Ricci, Emiliano
A1 Dreux, Marlène
YR 2021
UL http://medrxiv.org/content/early/2021/10/10/2021.09.01.21262969.abstract
AB Type I and III interferons (IFN-I/λ) are key antiviral mediators against SARS-CoV-2 infection. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) are the predominant IFN-I/λ source following their sensing of SARS-CoV-2-infected cells. Mechanistically, this short-range sensing by pDCs requires sustained integrin-mediated cell adhesion with infected cells. In turn, pDCs restrict viral spread by an IFN-I/λ response directed toward SARS-CoV-2-infected cells. This specialized function enables pDCs to efficiently turn-off viral replication, likely via a local response at the contact site with infected cells. By exploring the pDC response in SARS-CoV-2 patients, we further demonstrate that pDC responsiveness inversely correlates with the severity of the disease. The pDC response is particularly impaired in severe COVID-19 patients. Overall, we propose that pDC activation is essential to control SARS-CoV-2-infection. Failure to unfold this response could be key to understand severe cases of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding are include in the acknowledgment sectionAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ethics committee from EFS and HCLI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in the manuscript will be available